DS9 Document EFTA00489742

From To: Lesley Groff Subject: Re: Catching Up Date: Thu, 17 Jan 2019 17:26:03 +0000 Inline-Images: 1506365439123blobjpg Great. Thanks so much Lesley! thoHebe LLL cell: email: www.biohebe.com @BioHebe 2,Inline image On Thursday, January 17, 2019, 12:18:53 PM EST, Lesley Groff c › wrote: HI ..all is good! I will forward this on for you... Hope a is well with you too. Lesley On Jan 17, 2019, at 12:09 PM ,. wrote: Hi Lesley, I hope you're well! It's been a while since I was in touch! I emailed Jeffrey and Rich last night but wasn't sure that they still use the email addresses that I have. Thank you for forwarding this onto to them if you can. I hope to see you soon! My cell is: all the very best, if you ever need to reach me. EFTA00489742 BioHebe LLC cell: email: www.biohebe.com @BioHebe <1506365439123b1ob.jpg> From To: jeevaca ion gmal .com <[email protected]>• Sent: Wednesday, January 16, 2019, 11:22:06 PM EST Subject: Catching Up Dear Jeffrey I hope you've been well. I wanted to update you on what I've been up to for the last two years. I was also hoping to talk with you to see if I might use the foundation's Lexington office conference room from time to time for my work and what I could provide in exchange for that. I am cc'ing Rich because I'm not sure if you still use this email? Since working for your foundation, I continued to publish as a journalist writing mostly about genetic vectors (Newsweek, Techonomy etc). I then set up an LLC that provides business development for labs that have reversed age-driven or degenerative diseases. Most of the therapies are genetic vectors, and have to show remarkable results at the mouse level and beyond. Regenerative medicine is a rapidly evolving field, and one that forces the medical industry to shift their focus from addressing symptoms of disease to fundamental evolutionary shortfalls. So far, I placed a genetic vector at the National Institute of Medicine in France (that reversed glaucoma in mice using the neuroglobin gene) under formal licence review with a publicly traded pharma group here in the US. And I am collaborating with a lab at the University of Pittsburgh that has reversed cirrhosis/ end stage liver disease in rats using the master transcription gene in hepatocytes. The concept of the latter gene vector is really intriguing in that a master transcription gene completely restored liver function by rebalancing genetic expression and thus proteostasis. While I don't really need an office at this point, I do need access to a conference room from time to time and it would be hugely helpful if I could access the foundation's. If there was some work that I could do for the foundation in exchange, I would be delighted to do that. It would be wonderful to catch up with you as well. all the best, EFTA00489743 BioHebe LLC cell: email: www.biohebe.com @BioHebe <1506365439123b1ob.jpg> <1506365439123blobjpg><1506365439123blobjpg> EFTA00489744